Nabeel M. Bardeesy

This study shows metformin inhibits chromatin fragment egress from the nucleus, reducing cGAS-STING activation and chronic inflammation in aging.

This study uses SSZS MRI to detect early PDAC lesions and monitor treatment response and recurrence.

This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.

The paper identifies biparatopic antibodies targeting FGFR2 extracellular domain that effectively block FGFR2 fusion-driven cholangiocarcinoma signaling and growth.

The paper identifies D2HG and L2HG-induced O-2-hydroxyglutarylation with chiral specificity, revealing inhibitory effects on kinases MRCKA and SLK.

This study uses spatial transcriptomics to show that IPMN subtypes form a molecular continuum originating from gastric-type cells, with repeat element expression linked to disease progression.

This study shows that different FGFR2 mutations in cholangiocarcinoma affect biliary architecture based on the epithelial state of the cells, revealing distinct phenotypic consequences.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

The paper identifies a nucleus-to-mitochondria ROS sensing pathway involving CHK1 and SSBP1 that mediates resistance to platinum-based chemotherapies in ovarian cancers.

The paper shows NRF2 activation in KEAP1 wildtype lung cancers causes NADH-reductive stress, making them vulnerable to Complex I inhibition.

This study identifies ISL2 as an epigenetically silenced tumor suppressor in pancreatic cancer that regulates metabolism and presents therapeutic vulnerabilities.